By Sheeba M. | May 28, 2026

Federal Cannabis Scheduling Vote Expected June 15

TL;DR: Senate committee cleared for floor vote on federal descheduling bill June 15. Market pricing in ~60% probability of passage; MSO valuations could see 30-50% upside if bill moves to President’s desk. CRLBF and CURLF should benefit most.

Capitol Hill insiders are signaling that a pivotal moment for cannabis is within reach. After months of behind-the-scenes negotiations, the Senate Judiciary Committee voted 11-9 to advance a revised descheduling bill to the full Senate floor, with a vote scheduled for June 15.

The latest version—negotiated between Senator Wyden (D-OR) and Senator Paul (R-KY)—includes key compromises: banking access for licensed operators, state-level regulatory flexibility, and a 3-year transition period for existing MSOs to comply with new federal standards. This is significantly more favorable than the original proposal and has gained bipartisan backing.

Market Reaction So Far

Cannabis equities surged on the announcement, with Curaleaf (CRLBF) up 14% on the day and Curaleaf (CURLF) tracking similarly. The Street is pricing in roughly 60% probability of passage, which assumes some last-minute Republican defections in the House could stall the bill in September.

If the bill passes and reaches President Biden’s desk, federal banking access alone could unlock $5-10B in trapped MSO cash currently held offshore or in illiquid form. That capital redeployment would fund rapid consolidation and aggressive retail expansion.

Key Risks

What’s Priced In?

Current valuations assume ~60% passage odds. If the bill advances past June 15 committee vote and garners public statements of support from 5+ moderate Republicans, repricing to 75%+ probability would trigger another 10-15% MSO rally. Watch Greenrose (GTBPF) and Trulieve (TRSSF) for early breaks above 52-week resistance.

Sources

Track cannabis policy and market moves with the Weedstock Real-Time Tracker

Leave a Reply

📅 Yesterday's News & Older Articles →